67 related articles for article (PubMed ID: 23016588)
1. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.
Tagliaferri P; Caraglia M; Budillon A; Marra M; Vitale G; Viscomi C; Masciari S; Tassone P; Abbruzzese A; Venuta S
Cancer Immunol Immunother; 2005 Jan; 54(1):1-10. PubMed ID: 15693134
[TBL] [Abstract][Full Text] [Related]
2. Deregulation of Interferon Signaling in Malignant Cells.
Katsoulidis E; Kaur S; Platanias LC
Pharmaceuticals (Basel); 2010 Feb; 3(2):406-418. PubMed ID: 27713259
[TBL] [Abstract][Full Text] [Related]
3. The Immunotherapeutic Role of Type I and III Interferons in Melanoma and Non-Melanoma Skin Cancers.
Weir SA; Kc K; Shoaib S; Yusuf N
Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374093
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis to Identify Enhancer-Regulated Inflammation-Associated Genes in Lung Adenocarcinoma.
Li X; Li X; Ding L
Cancer Manag Res; 2021; 13():7115-7129. PubMed ID: 34539188
[TBL] [Abstract][Full Text] [Related]
5. RhoC Modulates Cell Junctions and Type I Interferon Response in Aggressive Breast Cancers.
Abraham HG; Ulintz PJ; Goo L; Yates JA; Little AC; Bao L; Wu Z; Merajver SD
Front Oncol; 2021; 11():712041. PubMed ID: 34513691
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral recombinant human interferon alpha-2a and vincristine combination therapy in canine transmissible venereal tumour.
Kanca H; Tez G; Bal K; Ozen D; Alcigir E; Atalay Vural S
Vet Med Sci; 2018 Nov; 4(4):364-372. PubMed ID: 30117719
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation.
Dicitore A; Grassi ES; Borghi MO; Gelmini G; Cantone MC; Gaudenzi G; Persani L; Caraglia M; Vitale G
J Endocrinol Invest; 2017 Jul; 40(7):761-770. PubMed ID: 28247216
[TBL] [Abstract][Full Text] [Related]
8. Human basonuclin 2 up-regulates a cascade set of interferon-stimulated genes with anti-cancerous properties in a lung cancer model.
Urgard E; Reigo A; Reinmaa E; Rebane A; Metspalu A
Cancer Cell Int; 2017; 17():18. PubMed ID: 28184177
[TBL] [Abstract][Full Text] [Related]
9. Interferon α Induces the Apoptosis of Cervical Cancer HeLa Cells by Activating both the Intrinsic Mitochondrial Pathway and Endoplasmic Reticulum Stress-Induced Pathway.
Shi WY; Cao C; Liu L
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827850
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
Sabbatino F; Wang Y; Scognamiglio G; Favoino E; Feldman SA; Villani V; Flaherty KT; Nota S; Giannarelli D; Simeone E; Anniciello AM; Palmieri G; Pepe S; Botti G; Ascierto PA; Ferrone CR; Ferrone S
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26851802
[TBL] [Abstract][Full Text] [Related]
11. The TEL-AML1 fusion protein of acute lymphoblastic leukemia modulates IRF3 activity during early B-cell differentiation.
de Laurentiis A; Hiscott J; Alcalay M
Oncogene; 2015 Dec; 34(49):6018-28. PubMed ID: 25893288
[TBL] [Abstract][Full Text] [Related]
12. Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-α, shows antitumor effect in vitro and in vivo.
Li M; Rao C; Pei D; Wang L; Li Y; Gao K; Wang M; Wang J
Cancer Cell Int; 2014 Jan; 14(1):8. PubMed ID: 24467885
[TBL] [Abstract][Full Text] [Related]
13. Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells.
Booy S; van Eijck CH; Dogan F; van Koetsveld PM; Hofland LJ
J Cell Mol Med; 2014 Mar; 18(3):492-502. PubMed ID: 24460759
[TBL] [Abstract][Full Text] [Related]
14. Type I interferons: ancient peptides with still under-discovered anti-cancer properties.
Caraglia M; Dicitore A; Marra M; Castiglioni S; Persani L; Sperlongano P; Tagliaferri P; Abbruzzese A; Vitale G
Protein Pept Lett; 2013 Apr; 20(4):412-23. PubMed ID: 23016588
[TBL] [Abstract][Full Text] [Related]
15. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways.
Caraglia M; Marra M; Tagliaferri P; Lamberts SW; Zappavigna S; Misso G; Cavagnini F; Facchini G; Abbruzzese A; Hofland LJ; Vitale G
Curr Cancer Drug Targets; 2009 Aug; 9(5):690-704. PubMed ID: 19508175
[TBL] [Abstract][Full Text] [Related]
16. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
Pfeffer LM; Dinarello CA; Herberman RB; Williams BR; Borden EC; Bordens R; Walter MR; Nagabhushan TL; Trotta PP; Pestka S
Cancer Res; 1998 Jun; 58(12):2489-99. PubMed ID: 9635566
[TBL] [Abstract][Full Text] [Related]
17. Translational and post-translational modifications of proteins as a new mechanism of action of alpha-interferon: review article.
Caraglia M; Vitale G; Marra M; Del Prete S; Lentini A; Budillon A; Beninati S; Abbruzzese A
Amino Acids; 2004 Jul; 26(4):409-17. PubMed ID: 15290347
[TBL] [Abstract][Full Text] [Related]
18. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors.
Vitale G; van Eijck CH; van Koetsveld Ing PM; Erdmann JI; Speel EJ; van der Wansem Ing K; Mooij DM; Colao A; Lombardi G; Croze E; Lamberts SW; Hofland LJ
Ann Surg; 2007 Aug; 246(2):259-68. PubMed ID: 17667505
[TBL] [Abstract][Full Text] [Related]
19. Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity.
Khine AA; Lingwood CA
J Cell Physiol; 2000 Jan; 182(1):97-108. PubMed ID: 10567921
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
